Re: Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
作者信息
Brewer Noel T, Reiter Paul L
出版信息
J Natl Cancer Inst. 2010 Oct 6;102(19):1517; author reply 1517-8. doi: 10.1093/jnci/djq326. Epub 2010 Sep 1.
Abstract
摘要
相似文献
1
Re: Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
J Natl Cancer Inst. 2010 Oct 6;102(19):1517; author reply 1517-8. doi: 10.1093/jnci/djq326. Epub 2010 Sep 1.
2
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
J Natl Cancer Inst. 2010 Mar 3;102(5):325-39. doi: 10.1093/jnci/djp534. Epub 2010 Feb 5.
3
Primary and secondary prevention of cervical cancer--opportunities and challenges.
J Natl Cancer Inst. 2009 Apr 1;101(7):439-40. doi: 10.1093/jnci/djp044. Epub 2009 Mar 24.
4
HPV 6, 11, 16, 18 vaccine in men. Inadequate assessment.
Prescrire Int. 2012 Sep;21(130):208.
5
Quadrivalent papillomavirus vaccine in women over age 26. Cervical screening must remain a priority.
Prescrire Int. 2011 May;20(116):121.
6
Human papillomavirus quadrivalent vaccine: a look behind the numbers.
Ann Pharmacother. 2009 Apr;43(4):740-4. doi: 10.1345/aph.1L483. Epub 2009 Mar 10.
7
[Prophylactic vaccination against human papillomavirus].
Ann Dermatol Venereol. 2007 Nov;134(11):882-5; quiz 881, 886. doi: 10.1016/s0151-9638(07)92841-0.
8
No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
J Infect. 2017 Apr;74(4):393-400. doi: 10.1016/j.jinf.2017.01.007. Epub 2017 Jan 23.
9
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.
Vaccine. 2008 Dec 9;26(52):6844-51. doi: 10.1016/j.vaccine.2008.09.073. Epub 2008 Oct 16.
10
Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil).
Drugs. 2006;66(9):1263-71; discussion 1272-3. doi: 10.2165/00003495-200666090-00008.
引用本文的文献
1
Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in Beijing, China: analysis of results from China's top 3 hospital, 2009-2019.
Virol J. 2020 Jul 13;17(1):104. doi: 10.1186/s12985-020-01383-1.
2
Evaluation of Association between Vaginal Infections and High-Risk Human Papillomavirus Types in Female Sex Workers in Spain.
ISRN Obstet Gynecol. 2012;2012:240190. doi: 10.5402/2012/240190. Epub 2012 Jul 31.
本文引用的文献
1
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
J Natl Cancer Inst. 2010 Mar 3;102(5):325-39. doi: 10.1093/jnci/djp534. Epub 2010 Feb 5.
2
Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women.
Sex Transm Infect. 2009 Dec;85(7):499-502. doi: 10.1136/sti.2009.037788. Epub 2009 Oct 16.
3
Efficacy of human papillomavirus vaccines: a systematic quantitative review.
Int J Gynecol Cancer. 2009 Oct;19(7):1166-76. doi: 10.1111/IGC.0b013e3181a3d100.
4
Evaluating the impact of human papillomavirus vaccines.
Vaccine. 2009 Jul 9;27(32):4355-62. doi: 10.1016/j.vaccine.2009.03.008. Epub 2009 Mar 13.
5
Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries.
Vaccine. 2006 Aug 31;24 Suppl 3:S3/233-41. doi: 10.1016/j.vaccine.2006.05.109.
Zotero 插件